DLG4 and major depressive disorder: Ketamine’s prevention of CRS-induced 4E-BP1 phosphorylation, PSD-95 and GluA1 immunocontent in the prefrontal cortex, reinforcing its characteristic of a prophylactic agent to manage individuals at-risk to develop MDD and anxiety (93).